- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Oncology
Volume 2012 (2012), Article ID 621685, 7 pages
DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression
1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
2Department of Pathology, Cleveland Clinics, Cleveland, OH 44195, USA
Received 14 May 2011; Revised 29 July 2011; Accepted 11 August 2011
Academic Editor: Kentaro Nakayama
Copyright © 2012 Malti Kshirsagar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- K. R. Cho and I. M. Shih, “Ovarian cancer,” Annual Review of Pathology, vol. 4, pp. 287–313, 2009.
- M. Köbel, S. E. Kalloger, N. Boyd et al., “Ovarian carcinoma subtypes are different diseases: implications for biomarker studies,” PLoS Medicine, vol. 5, no. 12, article e232, 2008.
- I. M. Shih and R. J. Kurman, “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis,” American Journal of Pathology, vol. 164, no. 5, pp. 1511–1518, 2004.
- K. Oka, T. Tanaka, T. Enoki et al., “DNA damage signaling is activated during cancer progression in human colorectal carcinoma,” Cancer Biology and Therapy, vol. 9, no. 3, pp. 246–252, 2010.
- J. B. M. Koorstra, S. M. Hong, C. Shi et al., “Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia,” Modern Pathology, vol. 22, no. 11, pp. 1439–1445, 2009.
- A. J. Yoon, J. Shen, R. M. Santella, D. J. Zegarelli, R. Chen, and I. B. Weinstein, “Activated checkpoint kinase 2 expression and risk for oral squamous cell carcinoma,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 12, pp. 2768–2772, 2007.
- F. Al-Ejeh, R. Kumar, A. Wiegmans, S. R. Lakhani, M. P. Brown, and K. K. Khanna, “Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes,” Oncogene, vol. 29, no. 46, pp. 6085–6098, 2010.
- J. W. Harper and S. J. Elledge, “The DNA damage response: ten years after,” Molecular Cell, vol. 28, no. 5, pp. 739–745, 2007.
- T. H. Stracker, T. Usui, and J. H. J. Petrini, “Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response,” DNA Repair, vol. 8, no. 9, pp. 1047–1054, 2009.
- S. Matsuoka, M. Huang, and S. J. Elledge, “Linkage of ATM to cell cycle regulation by the Chk2 protein kinase,” Science, vol. 282, no. 5395, pp. 1893–1897, 1998.
- J. Falck, N. Mailand, R. G. Syljuåsen, J. Bartek, and J. Lukas, “The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis,” Nature, vol. 410, no. 6830, pp. 842–847, 2001.
- I. M. Ward, X. Wu, and J. Chen, “Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks,” Journal of Biological Chemistry, vol. 276, no. 51, pp. 47755–47758, 2001.
- A. J. Yoon, J. Shen, H. C. Wu et al., “Expression of activated checkpoint kinase 2 and histone 2AX in exfoliative oral cells after exposure to ionizing radiation,” Radiation Research, vol. 171, no. 6, pp. 771–775, 2009.
- K. Stefanidis, D. Loutradis, L. V. Vassiliou et al., “Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells,” Gynecologic Oncology, vol. 111, no. 2, pp. 344–349, 2008.
- R. A. DiTullio, T. A. Mochan, M. Venere et al., “53BP1 functions in a ATM-dependent checkpoint pathway that is constitutively activated in human cancer,” Nature Cell Biology, vol. 4, no. 12, pp. 998–1002, 2002.
- I. M. Shih, J. J. C. Sheu, A. Santillan et al., “Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 14004–14009, 2005.
- T. L. Mao, C. Y. Hsu, M. J. Yen et al., “Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma,” Human Pathology, vol. 37, no. 9, pp. 1169–1175, 2006.
- K. Nakayama, N. Nakayama, N. Jinawath et al., “Amplicon profiles in ovarian serous carcinomas,” International Journal of Cancer, vol. 120, no. 12, pp. 2613–2617, 2007.
- C. Lukas, J. Falck, J. Bartkova, J. Bartek, and J. Lukas, “Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage,” Nature Cell Biology, vol. 5, no. 3, pp. 255–260, 2003.
- J. J. C. Sheu, B. Guan, J. H. Choi et al., “Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability,” Journal of Biological Chemistry, vol. 285, no. 49, pp. 38260–38269, 2010.
- V. G. Gorgoulis, L. V. F. Vassiliou, P. Karakaidos et al., “Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions,” Nature, vol. 434, no. 7035, pp. 907–913, 2005.
- J. Bartkova, Z. Hořejší, K. Koed et al., “DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis,” Nature, vol. 434, no. 7035, pp. 864–870, 2005.
- J. Bartkova, N. Rezaei, M. Liontos et al., “Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints,” Nature, vol. 444, no. 7119, pp. 633–637, 2006.
- R. Di Micco, M. Fumagalli, A. Cicalese et al., “Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication,” Nature, vol. 444, no. 7119, pp. 638–642, 2006.
- D. W. Kindelberger, Y. Lee, A. Miron et al., “Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship,” American Journal of Surgical Pathology, vol. 31, no. 2, pp. 161–169, 2007.
- C. P. Crum, R. Drapkin, A. Miron et al., “The distal fallopian tube: a new model for pelvic serous carcinogenesis,” Current Opinion in Obstetrics and Gynecology, vol. 19, no. 1, pp. 3–9, 2007.
- R. J. Kurman and I. M. Shih, “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory,” American Journal of Surgical Pathology, vol. 34, no. 3, pp. 433–443, 2010.
- K. Visvanathan, A. L. Gross, R. J. Kurman, R. Vang, and I. M. Shih, “Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics,” Journal of Oncology, Article ID 126295, 2010.
- S. Salvador, B. Gilks, M. Köbel, D. Huntsman, B. Rosen, and D. Miller, “The fallopian tube: primary site of most pelvic high-grade serous carcinomas,” International Journal of Gynecological Cancer, vol. 19, no. 1, pp. 58–64, 2009.
- G. Singer, R. J. Kurman, H. W. Chang, S. K. R. Cho, and I. M. Shih, “Diverse tumorigenic pathways in ovarian serous carcinoma,” American Journal of Pathology, vol. 160, no. 4, pp. 1223–1228, 2002.
- G. Singer, R. Oldt III, Y. Cohen et al., “Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 6, pp. 484–486, 2003.
- K. Nakayama, N. Nakayama, R. J. Kurman et al., “Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms,” Cancer Biology and Therapy, vol. 5, no. 7, pp. 779–785, 2006.
- S. Jones, T. L. Wang, I. M. Shih et al., “Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma,” Science, vol. 330, no. 6001, pp. 228–231, 2010.
- I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert et al., “Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential,” Oncogene, vol. 24, no. 6, pp. 1053–1065, 2005.
- I.-M. Shih, L. Chen, C. C. Wang, et al., “Distinct DNA methylation profiles in ovarian sreous neoplasms and their implications in ovarian carcinogenesis,” American Journal of Obstetrics & Gynecology, vol. 203, no. 6, pp. 584.e1–584.e22, 2010.
- C. Kerzendorfer and M. O'Driscoll, “Human DNA damage response and repair deficiency syndromes: linking genomic instability and cell cycle checkpoint proficiency,” DNA Repair, vol. 8, no. 9, pp. 1139–1152, 2009.
- D. Lydall, “Taming the tiger by the tail: modulation of DNA damage responses by telomeres,” EMBO Journal, vol. 28, no. 15, pp. 2174–2187, 2009.
- T. D. Halazonetis, V. G. Gorgoulis, and J. Bartek, “An oncogene-induced DNA damage model for cancer development,” Science, vol. 319, no. 5868, pp. 1352–1355, 2008.
- K. T. Kuo, T. L. Mao, Y. Feng et al., “DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma,” Clinical Cancer Research, vol. 16, no. 7, pp. 1997–2008, 2010.
- K. T. Kuo, B. Guan, Y. Feng et al., “Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas,” Cancer Research, vol. 69, no. 9, pp. 4036–4042, 2009.
- V. E. Anderson, M. I. Walton, P. D. Eve et al., “CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors,” Cancer Research, vol. 71, no. 2, pp. 463–472, 2011.